Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma

PROTEOMICS ◽  
2005 ◽  
Vol 5 (10) ◽  
pp. 2665-2679 ◽  
Author(s):  
Barabara Sitek ◽  
Jutta Lüttges ◽  
Katrin Marcus ◽  
Günter Klöppel ◽  
Wolff Schmiegel ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Gel Electrophoresis ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions ◽  
Difference Gel Electrophoresis

Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma

Pathology ◽  
2003 ◽  
Vol 35 (1) ◽  
pp. 14-24 ◽  
Author(s):  
Andrew V. Biankin ◽  
James G. Kench ◽  
Floriaan P. Dijkman ◽  
Sandra A. Biankin ◽  
Susan M. Henshall
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Molecular Pathogenesis ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions

Molecular characterization of early precursor lesions of pancreatic ductal adenocarcinoma

Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S4
Author(s):  
Lisa Frohn ◽  
Lena Häberle ◽  
Wolfgang Göring ◽  
Matthias Wirth ◽  
Irene Esposito
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Molecular Characterization ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions

Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma

Pathology ◽  
2003 ◽  
Vol 35 (1) ◽  
pp. 14-24 ◽  
Author(s):  
Andrew V. Biankin ◽  
James G. Kench ◽  
Floriaan P. Dijkman ◽  
Sandra A. Biankin ◽  
Susan M. Henshall
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Molecular Pathogenesis ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions

scholarly journals MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions

2010 ◽  
Vol 56 (4) ◽  
pp. 603-612 ◽  
Author(s):  
Maël Chalret du Rieu ◽  
Jérôme Torrisani ◽  
Janick Selves ◽  
Talal Al Saati ◽  
Anny Souque ◽  
...  
Keyword(s):  
Early Detection ◽  
Mouse Model ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Early Stage ◽  
Survival Rates ◽  
Ductal Adenocarcinoma ◽  
Early Event ◽  
Precursor Lesions ◽  
Tissue Samples ◽  
Ductal Cells

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has the poorest overall prognosis among gastrointestinal cancers; however, curative resection in early-stage PDAC greatly improves survival rates, indicating the importance of early detection. Because abnormal microRNA production is commonly detected in cancer, we investigated noninvasive precursor pancreatic intraepithelial neoplasia (PanIN) lesions for microRNA production as a potential early biomarker of PDAC. Methods: Pathologists identified and classified ductal lesions. We extracted total RNA from laser-capture microdissected PanIN tissue samples from a conditional KRAS(G12D) mouse model (n = 29) or of human origin (n = 38) (KRAS is v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). MicroRNA production was quantified by quantitative real-time PCR. Internal controls included 5S and U6 RNAs. Results: Production of microRNAs miR-21, miR-205, and miR-200 paralleled PanIN progression in the KRAS(G12D) mouse model, compared with microRNA production in samples of nonpathologic ducts. miR-21 demonstrated the highest relative concentrations in the precursor lesions. Interestingly, miR-205 and miR-21 up-regulation preceded phenotypic changes in the ducts. The production of microRNAs miR-21, miR-221, miR-222, and let-7a increased with human PanIN grade, with peak production occurring in hyperplastic PanIN-2/3 lesions. In situ hybridization analysis indicated miR-21 production to be concentrated in pathologic ductal cells. miR-21 production was regulated by KRAS(G12D) and epidermal growth factor receptor in PDAC-derived cell lines. Conclusions: Aberrant microRNA production is an early event in the development of PanIN. Our findings indicate that miR-21 warrants further investigation as a marker for early detection of PDAC.

scholarly journals miRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review

2015 ◽  
Vol 10 ◽  
pp. BMI.S27679 ◽  
Author(s):  
Bárbara Alemar ◽  
Cleandra Gregório ◽  
Patricia Ashton-Prolla
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Management ◽  
Positive Impact ◽  
Invasive Procedure ◽  
Prognostic Biomarkers ◽  
Premalignant Lesions ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions ◽  
Comprehensive Review

Pancreatic ductal adenocarcinoma (PDAC), a rare but lethal tumor, is difficult to diagnose without performing an invasive procedure. miRNAs are known to be deregulated in PDAC patients, and recent studies have shown that they can be used as diagnostic and prognostic of the disease. The detection of miRNAs in samples acquired through minimally or noninvasive procedures, such as serum, plasma, and saliva, can have a positive impact on the clinical management of these patients. This article is a comprehensive review of the major studies that have evaluated the expression of miRNAs as biomarkers in pancreatic cancer and its premalignant lesions.

scholarly journals Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry

2014 ◽  
Vol 138 (2) ◽  
pp. 220-228 ◽  
Author(s):  
Chanjuan Shi ◽  
Nipun Merchant ◽  
Guy Newsome ◽  
David M. Goldenberg ◽  
David V. Gold
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Pancreatitis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Early Stage ◽  
High Specificity ◽  
Intraepithelial Neoplasia ◽  
Tissue Microarrays ◽  
Ductal Adenocarcinoma ◽  
Precursor Lesions ◽  
Pancreatic Intraepithelial Neoplasia

Context.—PAM4 is a monoclonal antibody that shows high specificity for pancreatic ductal adenocarcinoma (PDAC) and its neoplastic precursor lesions. A PAM4-based serum immunoassay is able to detect 71% of early-stage patients and 91% with advanced disease. However, approximately 20% of patients diagnosed with chronic pancreatitis (CP) are also positive for circulating PAM4 antigen. The specificity of the PAM4 antibody is critical to the interpretation of the serum-based and immunohistochemical assays for detection of PDAC. Objective.—To determine whether PAM4 can differentiate PDAC from nonneoplastic lesions of the pancreas. Design.—Tissue microarrays of PDAC (N = 43) and surgical specimens from CP (N = 32) and benign cystic lesions (N = 19) were evaluated for expression of the PAM4 biomarker, MUC1, MUC4, CEACAM5/6, and CA19-9. Results.—PAM4 and monoclonal antibodies (MAbs) to MUC1, MUC4, CEACAM5/6, and CA19-9 were each reactive with the majority of PDAC cases; however, PAM4 was the only monoclonal antibody not to react with adjacent, nonneoplastic parenchyma. Although PAM4 labeled 19% (6 of 32) of CP specimens, reactivity was restricted to pancreatic intraepithelial neoplasia associated with CP; inflamed tissues were negative in all cases. In contrast, MUC1, MUC4, CEACAM5/6, and CA19-9 were detected in 90%, 78%, 97%, and 100% of CP, respectively, with reactivity also present in nonneoplastic inflamed tissue. Conclusions.—PAM4 was the only monoclonal antibody able to differentiate PDAC (and pancreatic intraepithelial neoplasia precursor lesions) from benign, nonneoplastic tissues of the pancreas. These results suggest the use of PAM4 for evaluation of tissue specimens, and support its role as an immunoassay for detection of PDAC.

Sign in / Sign up

Export Citation Format

Share Document